SCHEMBL21064332

SCHEMBL21064332

COC(O)c1ccc2[nH]cc(Cl)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 4/20 0.39
HTR1D P28221 2/20 0.36
MEN1 O00255 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
HTR1B P28222 1/20 0.35
MITF O75030 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAG3 Q9UGI9 1/20 0.35
PRKAG2 Q9UGJ0 1/20 0.35
PRKAB1 Q9Y478 1/20 0.35
SRC P12931 1/20 0.34
F7 P08709 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12376509 0.78 HTR1D (0.55) HTR1DMAPTHTR1BPRKAB2PRKAG1
SCHEMBL23490734 0.76 HTR1D (0.42) HTR1DMAPTHTR1BPRKAB2PRKAG1
SCHEMBL23030512 0.74 HTR2A (0.46) HTR1DMAPTHTR1BPRKAB2PRKAG1
SCHEMBL23030468 0.73 HTR1D (0.43) HTR1DMAPTHTR1BPRKAB2PRKAG1
SCHEMBL6203514 0.72 SLC6A2 (0.49) LMNAIDO1CYP2D6
SCHEMBL29055659 0.71 GPR84 (0.62) NR4A2HTR1DMEN1MAPTKMT2A
SCHEMBL7220652 0.70 NR4A2 (0.36) NR4A2HTR1DMEN1MAPTKMT2A
SCHEMBL20287858 0.70 PRKAB2 (0.37) NR4A2MAPTLMNAPRKAB2PRKAG1
SCHEMBL3388496 0.69 GPR84 (0.59) NR4A2MEN1KMT2ARAB9AGPR84
SCHEMBL21669262 0.68 CYP3A4 (0.45) LMNACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10308637-B2 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. (BB) 2019-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10308637-B2 Therapeutic inhibitory compounds KLKB1, SERPINB1, SERPINE1 NR4A2 3792/4885HTR1D 2492/4885MEN1 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.